Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 18 and 80 years old (male or female).
- People who have been diagnosed with a cancer that tests positive for a protein called EGFR, as confirmed by a specialist pathologist.
- People whose cancer (either the original tumour or one that has spread) measures 1.5 cm or larger, as shown by imaging scans (such as ultrasound, mammogram, CT, or MRI) or a physical examination.
- People who are able to give their informed consent to participate.
- Women who are not currently pregnant or breastfeeding. This includes women who have had both ovaries or their uterus surgically removed, women who have gone through menopause (no periods for more than 1 year), or women of childbearing age who have a negative pregnancy test taken within 24 hours before receiving the study imaging agent.
- People with a general health and activity level rated as 0, 1, or 2 on the WHO performance scale — meaning people who are fully active or able to carry out light daily activities, with or without some limitations (confirm with trial site for exact definitions).
- People who have not previously received any anti-EGFR antibody treatments.
Who may not be able to join:
- People who are unable to lie still or remain in a PET imaging scanner for up to 60 minutes per session.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 306-655-2932
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The observation of differences in 89Zr-DFO-nimotuzumab uptake between the tumors and normal tissues using PET/CT.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.